Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.2 (
PDK1
)
2,238
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin-like growth factor 1 (IGF-1) and
plasminogen activator inhibitor-1
(
PAI-1
) appear to play a crucial role in a number of processes associated with growth and tissue remodelling. IGF-1 was shown to enhance
PAI-1
expression in primary hepatocytes and HepG2 hepatoma cells, but the molecular mechanisms underlying this effect have not been fully elucidated. In this study, we investigated the transcriptional mechanism and the signaling pathway by which IGF-1 mediates induction of
PAI-1
expression in HepG2 cells. By using human
PAI-1
promoter reporter gene assays we found that mutation of the hypoxia responsive element (HRE), which could bind hypoxia-inducible factor-1 (HIF-1), nearly abolished the induction by IGF-1. We found that IGF-1-induced up-regulation of
PAI-1
expression was associated with activation of HIF-1 alpha. Furthermore,IGF-1 enhanced HIF-1alpha protein levels and HIF-1 DNA-binding to each HRE,E4 and E5 as shown by EMSA. Mutation of the E-boxes, E4 and E5, did not affect the IGF-1-dependent induction of
PAI-1
promoter constructs under normoxia but abolished the effect of IGF-1 under hypoxia. Inhibition of either the PI3K by LY294002 or ERK1/2 by U0126 reduced HIF-1alpha protein levels while both inhibitors together completely abolished the IGF-1 effect on HIF-1alpha. Remarkably, transfection of HepG2 cells with vectors expressing a dominant-negative
PDK1
or the PKB inhibitor, TRB3, did not influence while dominant-negative Raf inhibited the IGF-1 effect on HIF-1alpha. Thus, IGF-1 activates human
PAI-1
gene expression through activation of the PI3-kinase and ERK1/2 via HIF-1alpha.
...
PMID:Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. 1596 5
Enhanced levels of
plasminogen activator inhibitor-1
(
PAI-1
) are considered to be a risk factor for pathological conditions associated with hypoxia or hyperinsulinemia. The expression of the
PAI-1
gene is increased by insulin in different cells, although, the molecular mechanisms behind insulin-induced
PAI-1
expression are not fully known yet. Here, we show that insulin upregulates human
PAI-1
gene expression and promoter activity in HepG2 cells and that mutation of the hypoxia-responsive element (HRE)-binding hypoxia-inducible factor-1 (HIF-1) abolished the insulin effects. Mutation of E-boxes E4 and E5 abolished the insulin-dependent activation of the
PAI-1
promoter only under normoxia, but did not affect it under hypoxia. Furthermore, the insulin effect was associated with activation of HIF-1alpha via mitogen-activated protein kinases (MAPKs) but not
PDK1
and PKB in HepG2 cells. Furthermore, mutation of a putative FoxO1 binding site which was supposed to be involved in insulin-dependent
PAI-1
gene expression influenced the insulin-dependent activation only under normoxia. Thus, insulin-dependent
PAI-1
gene expression might be regulated by the action of both HIF-1 and FoxO1 transcription factors.
...
PMID:The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. 1738 80
The mTOR signaling plays an integral role in cellular homeostasis controlling the transition between the catabolic and anabolic states. Originally approved as immunosuppressive agents preventing allograft rejection, inhibitors of mTOR signaling have recently entered the arena of cancer therapy. Using rapamycin derivative (RAD001) as a prototype inhibitor, we aimed to systematically analyze the molecular mechanisms underlying the pleiotropic effects of mTOR signaling. Using proliferation- and clonogenic survival assays, a preferential sensitivity of microvascular endothelial cells (HDMVEC) followed by fibroblasts and U87 gliblastoma to RAD001 treatment was found. In contrast, lung- and prostate tumor cells demonstrated relative resistance against RAD001 treatment. In co-culture with fibroblasts, RAD001 exerted potent antiangiogenic effects by inhibiting endothelial cell tube formation. Further, RAD001 treatment efficiently prevented tumor growth in U87 tumor xenografts. Integrative transcriptome analysis was performed to decipher the molecular mechanism underlying RAD001 -induced anti-tumor and antiangiogenic effects. The predominant expression pattern was downregulation of genes after RAD001 treatment in all three sensitive cell types. Among the RAD001 downregulated genes, a transcriptional network was discovered enriched for genes related to angiogenesis processes and extracellular matrix remodeling, e.g., VEGF, HIF1A, CXCLs, IL6, FN,
PAI-1
or NRP1. Of note, key components of PI3K upstream (
PDK1
) as well as mTORC2 downstream signaling (SGK1, NDRG) were downregulated by RAD001. Decreased expression of IMPDH and 139 common gene targets between mycophenolic acid and RAD001 suggested in part shared mechanisms underlying their antiangiogenic and immunosuppressive effects. In summary, key genetic participants governing anti-tumor and anti-angiogenic effects of mTOR inhibition were identified.
...
PMID:Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. 2353 May 2
Glioblastoma (GB) is the most common and deadly type of primary malignant brain tumor with an average patient survival of only 15-17 months. GBs typically have hypoxic regions associated with aggressiveness and chemoresistance. Using patient derived GB cells, we characterized how GB responds to hypoxia. We noted a hypoxia-dependent glycolytic switch characterized by the up-regulation of HK2, PFKFB3, PFKFB4, LDHA,
PDK1
,
SLC2A1
/GLUT-1,
CA9
/CAIX, and
SLC16A3
/MCT-4. Moreover, many proangiogenic genes and proteins, including VEGFA, VEGFC, VEGFD,
PGF
/PlGF, ADM, ANGPTL4, and
SERPINE1/
PAI-1
were up-regulated during hypoxia. We detected the hypoxic induction of invasion proteins, including the plasminogen receptor, S100A10, and the urokinase plasminogen activator receptor, uPAR. Furthermore, we observed a hypoxia-dependent up-regulation of the autophagy genes,
BNIP-3
and
DDIT4
and of the multi-functional protein, NDRG1 associated with GB chemoresistance; and down-regulation of
EGR1
and
TFRC
(Graphical abstract). Analysis of GB patient cohorts' revealed differential expression of these genes in patient samples (except
SLC16A3
) compared to non-neoplastic brain tissue. High expression of
SLC2A1
,
LDHA
,
PDK1
,
PFKFB4
,
HK2
,
VEGFA
,
SERPINE1
,
TFRC
, and
ADM
was associated with significantly lower overall survival. Together these data provide important information regarding GB response to hypoxia which could support the development of more effective treatments for GB patients.
...
PMID:Investigating Glioblastoma Response to Hypoxia. 3286 90